Lupin’s Pithampur facility inspection concluded by US FDA without any observations

Pharma major Lupin Limited (Lupin) announced today the successful completion of a GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Pithampur manufacturing facility – Unit 1 without any observations. The inspection which started on Monday, July 24th concluded today afternoon.


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top